Home NDC 63020-765 MIMRYLO
Product NDC 63020-765
11-digit product format 630200765
Labeler code 63020
Product ID 63020-765_5dc25285-a184-4caa-9ce2-a7ff3f096372
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name rusfertide
Dosage form KIT
Route SUBCUTANEOUS
Labeler Takeda Pharmaceuticals America, Inc.
Application NDA220605
Marketing category NDA
Marketing start 2026-08-28
NDC exclude flag No
Listing certified through 2027-12-31
Current FDA listing Yes Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 5 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N220605-001 MIMRYLO RUSFERTIDE ACETATE EQ 9.5MG BASE/VIAL POWDER / SUBCUTANEOUS RLD, RS 2026-08-28 N220605-002 MIMRYLO RUSFERTIDE ACETATE EQ 19MG BASE/VIAL POWDER / SUBCUTANEOUS RLD, RS 2026-08-28 N220605-003 MIMRYLO RUSFERTIDE ACETATE EQ 28MG BASE/VIAL POWDER / SUBCUTANEOUS RLD, RS 2026-08-28 N220605-004 MIMRYLO RUSFERTIDE ACETATE EQ 41MG BASE/VIAL POWDER / SUBCUTANEOUS RLD, RS 2026-08-28 N220605-005 MIMRYLO RUSFERTIDE ACETATE EQ 54MG BASE/VIAL POWDER / SUBCUTANEOUS RLD, RS 2026-08-28
Orange Book patents# Current patent rows page 1 of 1 · 30 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N220605-001 10030061 2034-03-17 Drug substance, Drug product 2026-09-18 N220605-001 10442846 2034-03-17 U-4600 Drug substance, Drug product 2026-09-18 N220605-001 10501515 2034-03-17 U-4600 Drug substance 2026-09-18 N220605-001 11807674 2034-03-17 U-4600 Drug product 2026-09-18 N220605-001 12269856 2034-03-17 U-4600 2026-09-18 N220605-001 9822157 2034-03-17 Drug substance, Drug product 2026-09-18 N220605-002 10030061 2034-03-17 Drug substance, Drug product 2026-09-18 N220605-002 10442846 2034-03-17 U-4600 Drug substance, Drug product 2026-09-18 N220605-002 10501515 2034-03-17 U-4600 Drug substance 2026-09-18 N220605-002 11807674 2034-03-17 U-4600 Drug product 2026-09-18 N220605-002 12269856 2034-03-17 U-4600 2026-09-18 N220605-002 9822157 2034-03-17 Drug substance, Drug product 2026-09-18 N220605-003 10030061 2034-03-17 Drug substance, Drug product 2026-09-18 N220605-003 10442846 2034-03-17 U-4600 Drug substance, Drug product 2026-09-18 N220605-003 10501515 2034-03-17 U-4600 Drug substance 2026-09-18 N220605-003 11807674 2034-03-17 U-4600 Drug product 2026-09-18 N220605-003 12269856 2034-03-17 U-4600 2026-09-18 N220605-003 9822157 2034-03-17 Drug substance, Drug product 2026-09-18 N220605-004 10030061 2034-03-17 Drug substance, Drug product 2026-09-18 N220605-004 10442846 2034-03-17 U-4600 Drug substance, Drug product 2026-09-18 N220605-004 10501515 2034-03-17 U-4600 Drug substance 2026-09-18 N220605-004 11807674 2034-03-17 U-4600 Drug product 2026-09-18 N220605-004 12269856 2034-03-17 U-4600 2026-09-18 N220605-004 9822157 2034-03-17 Drug substance, Drug product 2026-09-18 N220605-005 10030061 2034-03-17 Drug substance, Drug product 2026-09-18 N220605-005 10442846 2034-03-17 U-4600 Drug substance, Drug product 2026-09-18 N220605-005 10501515 2034-03-17 U-4600 Drug substance 2026-09-18 N220605-005 11807674 2034-03-17 U-4600 Drug product 2026-09-18 N220605-005 12269856 2034-03-17 U-4600 2026-09-18 N220605-005 9822157 2034-03-17 Drug substance, Drug product 2026-09-18
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 5 matching rows.
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-11-14 07:37:17 2026-10 N220605-001 MIMRYLO EQ 9.5MG BASE/VIAL POWDER / SUBCUTANEOUS RLD, RS 2026-08-28 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-002 MIMRYLO EQ 19MG BASE/VIAL POWDER / SUBCUTANEOUS RLD, RS 2026-08-28 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-003 MIMRYLO EQ 28MG BASE/VIAL POWDER / SUBCUTANEOUS RLD, RS 2026-08-28 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-004 MIMRYLO EQ 41MG BASE/VIAL POWDER / SUBCUTANEOUS RLD, RS 2026-08-28 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-005 MIMRYLO EQ 54MG BASE/VIAL POWDER / SUBCUTANEOUS RLD, RS 2026-08-28 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N220605-001 MIMRYLO EQ 9.5MG BASE/VIAL POWDER / SUBCUTANEOUS RLD, RS 2026-08-28 c2088c7a36db…2026-10-15 13:18:30 2026-09 N220605-002 MIMRYLO EQ 19MG BASE/VIAL POWDER / SUBCUTANEOUS RLD, RS 2026-08-28 c2088c7a36db…2026-10-15 13:18:30 2026-09 N220605-003 MIMRYLO EQ 28MG BASE/VIAL POWDER / SUBCUTANEOUS RLD, RS 2026-08-28 c2088c7a36db…2026-10-15 13:18:30 2026-09 N220605-004 MIMRYLO EQ 41MG BASE/VIAL POWDER / SUBCUTANEOUS RLD, RS 2026-08-28 c2088c7a36db…2026-10-15 13:18:30 2026-09 N220605-005 MIMRYLO EQ 54MG BASE/VIAL POWDER / SUBCUTANEOUS RLD, RS 2026-08-28 c2088c7a36db…2026-09-14 22:38:34 2026-08 N220605-001 MIMRYLO EQ 9.5MG BASE/VIAL POWDER / SUBCUTANEOUS RLD, RS 2026-08-28 84e616aacf4f…2026-09-14 22:38:34 2026-08 N220605-002 MIMRYLO EQ 19MG BASE/VIAL POWDER / SUBCUTANEOUS RLD, RS 2026-08-28 84e616aacf4f…2026-09-14 22:38:34 2026-08 N220605-003 MIMRYLO EQ 28MG BASE/VIAL POWDER / SUBCUTANEOUS RLD, RS 2026-08-28 84e616aacf4f…2026-09-14 22:38:34 2026-08 N220605-004 MIMRYLO EQ 41MG BASE/VIAL POWDER / SUBCUTANEOUS RLD, RS 2026-08-28 84e616aacf4f…2026-09-14 22:38:34 2026-08 N220605-005 MIMRYLO EQ 54MG BASE/VIAL POWDER / SUBCUTANEOUS RLD, RS 2026-08-28 84e616aacf4f…
Observed Orange Book patent history# Patent history page 1 of 2 · 60 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N220605-001 10030061 2034-03-17 Drug substance, Drug product 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-001 10442846 2034-03-17 U-4600 Drug substance, Drug product 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-001 10501515 2034-03-17 U-4600 Drug substance 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-001 11807674 2034-03-17 U-4600 Drug product 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-001 12269856 2034-03-17 U-4600 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-001 9822157 2034-03-17 Drug substance, Drug product 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-002 10030061 2034-03-17 Drug substance, Drug product 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-002 10442846 2034-03-17 U-4600 Drug substance, Drug product 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-002 10501515 2034-03-17 U-4600 Drug substance 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-002 11807674 2034-03-17 U-4600 Drug product 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-002 12269856 2034-03-17 U-4600 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-002 9822157 2034-03-17 Drug substance, Drug product 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-003 10030061 2034-03-17 Drug substance, Drug product 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-003 10442846 2034-03-17 U-4600 Drug substance, Drug product 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-003 10501515 2034-03-17 U-4600 Drug substance 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-003 11807674 2034-03-17 U-4600 Drug product 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-003 12269856 2034-03-17 U-4600 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-003 9822157 2034-03-17 Drug substance, Drug product 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-004 10030061 2034-03-17 Drug substance, Drug product 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-004 10442846 2034-03-17 U-4600 Drug substance, Drug product 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-004 10501515 2034-03-17 U-4600 Drug substance 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-004 11807674 2034-03-17 U-4600 Drug product 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-004 12269856 2034-03-17 U-4600 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-004 9822157 2034-03-17 Drug substance, Drug product 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-005 10030061 2034-03-17 Drug substance, Drug product 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-005 10442846 2034-03-17 U-4600 Drug substance, Drug product 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-005 10501515 2034-03-17 U-4600 Drug substance 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-005 11807674 2034-03-17 U-4600 Drug product 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-005 12269856 2034-03-17 U-4600 2026-09-18 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220605-005 9822157 2034-03-17 Drug substance, Drug product 2026-09-18 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N220605-001 10030061 2034-03-17 Drug substance, Drug product 2026-09-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N220605-001 10442846 2034-03-17 U-4600 Drug substance, Drug product 2026-09-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N220605-001 10501515 2034-03-17 U-4600 Drug substance 2026-09-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N220605-001 11807674 2034-03-17 U-4600 Drug product 2026-09-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N220605-001 12269856 2034-03-17 U-4600 2026-09-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N220605-001 9822157 2034-03-17 Drug substance, Drug product 2026-09-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N220605-002 10030061 2034-03-17 Drug substance, Drug product 2026-09-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N220605-002 10442846 2034-03-17 U-4600 Drug substance, Drug product 2026-09-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N220605-002 10501515 2034-03-17 U-4600 Drug substance 2026-09-18 c2088c7a36db…2026-10-15 13:18:30 2026-09 N220605-002 11807674 2034-03-17 U-4600 Drug product 2026-09-18 c2088c7a36db…
Observed Orange Book exclusivity history# Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
Finished product Yes
Brand name base MIMRYLO
Listing expiration 2027-12-31 Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join MIMRYLO RUSFERTIDE Takeda Pharmaceuticals America, Inc. 101aff01-31ed-4841-a8b6-0a5a8503189b 2026-11-07 Warnings, Adverse reactions Exact identifier application applno (NDA): 220605 application number: NDA220605 ndc (product): 63020-765
Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Sample Exclude flag Status 63020-765-60 63020076560 1 KIT in 1 CARTON (63020-765-60) * 54 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL (63020-760-60) * .6 mL in 1 SYRINGE (63020-600-05) 1 kit 2026-08-28 No No Current